TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021

15 December 2021 – Clinical Spotlight | TRALA Study of TLX66 for Autologous Stem Cell Transplantation in AL-Amyloidosis Presented at American Society of Hematology Annual Meeting 2021 

Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosisstudy of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab) in patients with Systemic Amyloid Light Chain Amyloidosis (AL-Amyloidosis), presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Results were presented by Dr. Kim Orchard, Consultant Hematologist at University Hospital Southampton, and principal investigator for the TRALA study. 

The TRALA study is also featured in the American Society of Hematology Blood magazine, November Edition, here.

 

Autologous Stem Cell Transplantation in AL-Amyloidosis following Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody as Sole Conditioning is Associated with Low Toxicity and Demonstrable Disease Responses

Autologous Stem Cell Transplantation in AL-Amyloidosis following Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody as Sole Conditioning is Associated with Low Toxicity and Demonstrable Disease Responses

 

To download the poster presentation in high-resolution PDF format please click here. 

To view a video of Dr. Kim Orchard presenting the study at ASH, please click here. 

TLX66 has not received a marketing authorisation in any jurisdiction. 

To return to Telix’s homepage please click here.